Cerviray AI
Cerviray AI is the world's first AI-based cervical cancer screening product, developed by AIDOT Inc. By combining advanced deep learning algorithms with cervical imaging technology, it provides fast and accurate screening, helping healthcare professionals save lives. Additionally, it is the only leading AI capable of classifying cervical severity into four categories—Normal, CIN1, CIN2-3, and CIN3+—which are considered the gold standard in histopathological diagnosis.
Developed in collaboration with Korea University Anam Hospital and Seoul National University Bundang Hospital, Cerviray AI has received Class III approval from the KFDA. With 98% sensitivity and 91% specificity, it delivers results in under one minute. Whether in urban hospitals or remote clinics, Cerviray AI revolutionizes accessibility to cervical cancer screening.
Performance Metrics
Cerviray AI in Global Market
Cerviray AI is currently deployed in multiple countries. Discover our expanding reach.
Detailed Activity
South Korea
MFDS medical device class 3 approval
Distributed to 250+ hospitals and clinics
Kuwait
Sample product registration completed
Product registration in progress
Mongolia
Successful commercialization across Mongolia
Mobile screenings carried out actively
Bolivia
AGEMED registration completed
Distributed to 100 hospitals and clinics
Vietnam
Vietnam MOH regulatory approval
Promoting ODA project
Indonesia
Indonesia AKL certification for medical devices
Mexico
Product registration in progress
Conducting 500 cases of clinical trial
Honduras
Product registration in progress
NIA government project successfully completed
